

Navneeta Bharadvaja

with the headingandabstract (2) (1)

Document Details

Submission ID

trn:oid:::27535:140527179

Submission Date

May 26, 2026, 12:02 PM GMT+0

Download Date

May 26, 2026, 12:05 PM GMT+0

File Name

with the headingandabstract (2) (1).docx

File Size

2.4 MB

24 Pages

5,185 Words

33,244 Characters

10% Overall Similarity

The combined total of all matches, including overlapping sources, for each database.

Filtered from the Report

- Bibliography
- Cited Text

Match Groups

- 48 Not Cited or Quoted 10%**
Matches with neither in-text citation nor quotation marks
- 0 Missing Quotations 0%**
Matches that are still very similar to source material
- 0 Missing Citation 0%**
Matches that have quotation marks, but no in-text citation
- 0 Cited and Quoted 0%**
Matches with in-text citation present, but no quotation marks

Top Sources

- 6% Internet sources
- 6% Publications
- 6% Submitted works (Student Papers)

Integrity Flags

0 Integrity Flags for Review

Our system's algorithms look deeply at a document for any inconsistencies that would set it apart from a normal submission. If we notice something strange, we flag it for you to review.

A Flag is not necessarily an indicator of a problem. However, we'd recommend you focus your attention there for further review.

Match Groups

- 48 Not Cited or Quoted 10%**
Matches with neither in-text citation nor quotation marks
- 0 Missing Quotations 0%**
Matches that are still very similar to source material
- 0 Missing Citation 0%**
Matches that have quotation marks, but no in-text citation
- 0 Cited and Quoted 0%**
Matches with in-text citation present, but no quotation marks

Top Sources

- 6% Internet sources
- 6% Publications
- 6% Submitted works (Student Papers)

Top Sources

The sources with the highest number of matches within the submission. Overlapping sources will not be displayed.

1	Internet	assets-eu.researchsquare.com	<1%
2	Internet	www.rumc.edu.my	<1%
3	Student papers	Krea University on 2026-05-23	<1%
4	Publication	Ahmad Al-Bitar, Ghadeer Taleb, Lujain AlKhaiat, Mohammad Alkari, Rafat Horoub...	<1%
5	Student papers	American Public University System on 2026-05-23	<1%
6	Internet	www.drug2gene.com	<1%
7	Internet	pmc.ncbi.nlm.nih.gov	<1%
8	Publication	Divya Shaji. "Identification of Novel Human Serum Albumin (SA) Inhibitors from S...	<1%
9	Publication	Bai-Yang Lin, Li Bai, Sheng-Long Wang. "Regulation of the Nrf2/HO-1 pathway in c...	<1%
10	Student papers	Delhi Technological University on 2026-05-22	<1%

11	Publication	Hosakatte Niranjana Murthy. "Bioactive Compounds in Leafy Vegetables", CRC Pr...	<1%
12	Internet	digital.library.unt.edu	<1%
13	Student papers	University of New England on 2010-06-05	<1%
14	Student papers	University of Nottingham on 2026-05-06	<1%
15	Internet	saspublishers.com	<1%
16	Publication	Jiasheng Cao, Jiahao Hu, Jiliang Shen, Bin Zhang et al. "Identification of Publicatio...	<1%
17	Student papers	Universiti Malaysia Sabah on 2023-10-06	<1%
18	Internet	cyberleninka.org	<1%
19	Publication	De-Xing HOU. "Flavonoids as Protein Kinase Inhibitors for Cancer Chemopreventi...	<1%
20	Student papers	Delhi Technological University on 2026-05-04	<1%
21	Student papers	Malaviya National Institute of Technology on 2026-02-04	<1%
22	Publication	Natasha Bokhari, Asif Ali, Sadaf Nausheen, Abida Yasmeen, Muhammad Awais An...	<1%
23	Publication	Zhang, X.. "Akt, FoxO and regulation of apoptosis", BBA - Molecular Cell Research,...	<1%
24	Internet	brieflands.com	<1%

25	Internet	public-pages-files-2025.frontiersin.org	<1%
26	Internet	www.dovepress.com	<1%
27	Publication	Lianming Du, Chaoyue Geng, Qianglin Zeng, Ting Huang, Jie Tang, Yiwen Chu, Kel...	<1%
28	Publication	Tharansia Ramachandran, Gayathri Rengasamy, J. Selvaraj, V. Vishnu Priya. "Cyto...	<1%
29	Student papers	Universidade de Coimbra on 2025-09-29	<1%
30	Student papers	University of Portsmouth on 2019-04-28	<1%
31	Student papers	University of Stellenbosch, South Africa on 2013-01-25	<1%
32	Publication	Zhongwen Qi, Zhipeng Yan, Yueyao Wang, Nan Ji, Xiaoya Yang, Ao Zhang, Meng Li...	<1%
33	Internet	dokumen.pub	<1%
34	Internet	hereditasjournal.biomedcentral.com	<1%
35	Internet	ir.vistas.ac.in	<1%
36	Internet	medlib.mef.hr	<1%
37	Publication	Tissier, R.. "Pharmacological postconditioning with the phytoestrogen genistein",...	<1%
38	Publication	"6 Gallbladder and Biliary Tract", Georg Thieme Verlag KG, 2018	<1%

39

Student papers

Delhi Technological University on 2026-05-24

<1%

Molecular Docking-Based Evaluation of Quercetin as a Multi-Target Therapeutic Agent in Estrogen-Associated Gallbladder Carcinogenesis.

MASTERS OF SCIENCE
IN BIOTECHNOLOGY

VICTORIA SIRO
24/MSCBIO/065

Under the Supervision of
Dr. NAVNEETA BHARADVAJA
Associate professor, Dept. of Biotechnology
Delhi Technological University, Delhi



Department of Biotechnology

DELHI TECHNOLOGICAL UNIVERSITY
(Formerly Delhi College of Engineering)
Shahbad Daultpur, Main Bawana Road, Delhi-110042, India

May, 2026

ABSTRACT

Gallbladder carcinoma (GBC) is an intense and highly invasive malignant cancer of the biliary tract associated with unfavorable prognosis and high mortality due to late-stage

diagnosis. Chronic inflammation, oxidative stress, hormonal imbalance, and dysregulation of signaling pathways such as PI3K/AKT, MAPK, and NF- κ B play major roles in the progression of estrogen-associated gallbladder carcinogenesis.

Estrogen-mediated signaling further contributes to tumor development by promoting gallstone formation, abnormal cell proliferation, angiogenesis, and resistance to apoptosis. Considering the complex and multi-factorial nature of gallbladder cancer, there is a growing need for therapeutic agents capable of targeting multiple molecular pathways simultaneously. The present study aimed to evaluate the multi-target therapeutic potential of quercetin, a naturally occurring flavonoid, against estrogen-associated gallbladder carcinogenesis using molecular docking and network pharmacology approaches. Potential protein targets of quercetin were identified using SwissTargetPrediction, while gallbladder disease-associated genes were collected from GeneCards. Intersection analysis revealed seven overlapping target genes associated with disease progression. Interaction analysis demonstrated the presence of multiple hydrogen bonds and hydrophobic interactions within the active binding site, confirming structural compatibility between quercetin and the target protein. Visualization studies using PyMOL and Discovery Studio further validated the docking results. The findings of this study suggest that quercetin possesses significant multi-target therapeutic potential by modulating critical signalling pathways involved in gallbladder carcinogenesis, particularly the PI3K/AKT pathway. Therefore, quercetin may serve as a promising natural compound for the development of future therapeutic strategies against estrogen-associated gallbladder cancer. Further *in vitro*, *in vivo*, and clinical studies are recommended to validate its therapeutic efficacy and safety.

Keywords

Gallbladder carcinoma; Quercetin; Molecular docking; PI3K/AKT pathway; Estrogen signalling; Network pharmacology; AKT1; Flavonoids; Autodocking Vina; Multi-target therapy; Gallbladder cancer; Protein–ligand interaction; Computational biology; Anticancer activity; Therapeutic targets

CONTENTS

	Title	Page No.
	Candidate's Declaration	i
	Certificate by Supervisor	ii
	Abstract	iii
	Acknowledgement	iv
	List of Figures	v
	List of Tables	vi
	Abbreviations	vii
Chapter1	Introduction	1
1.1	Gallbladder Carcinoma and Pathogenesis	1
1.2	Role of Estrogen in Gallbladder Carcinogenesis	3
1.3	Need for Multi-Target Therapeutic Approaches	4
1.4	Quercetin as a Therapeutic Compound	5
1.5	Objectives of the Study	6
Chapter2	Literature Review	7
2.1	Overview of Gallbladder Carcinoma	7
2.2	Relation Between Estrogen and Gallbladder Carcinoma	10
2.3	Quercetin as an Anticancer Compound	12
2.4	Quercetin and PI3K/AKT/mTOR Signaling	14
2.5	Estrogen Receptor and PI3K/AKT	16

	Title	Page No.
	Crosstalk	
2.6	Quercetin in Hormone-Related Disorders and Cancer	17
2.7	Flavonoids Targeting PI3K/Akt/mTOR Pathway	18
2.8	Molecular Docking Methodology	19
2.9	Molecular Docking and ADME Profiling	20
Chapter3	Methodology	21
3.1	Computational Resources and Databases Used	21
3.1.1	Databases and Tools Utilized	21
3.1.2	Software Utilized	24
3.2	Objectives and Experimental Design	26
3.2.1	Evaluation of Multi-Target Therapeutic Potential of Quercetin	26
3.2.2	Molecular Docking-Based Validation of Target Proteins	30
Chapter4	Results and Discussion	33
4.1	Results and Discussion for Objective 1	33
4.1.1	Identification of Potential Targets	33
4.2	Results and Discussion for Objective 2	36
4.2.1	Molecular Docking Analysis	36
4.2.2	Validation of Therapeutic Potential Through Docking	40
Chapter5	Conclusion, Future Perspectives and Social Impact	42
5.1	Conclusion	42
5.2	Future Perspectives	44
5.3	Social Impact	45
	References	47

List of figures

Figure 1: 3D image (ball and stick) of quercetin obtained from pubchem. Co-ordinates are also downloaded in sdf format

Figure 2: 3D structure of AKT1(PDB ID-3O96) retrieved from PDB

Figure 3: SwissTargetPrediction (smile notation) from the PubChem to the SwissTargetPrediction website (<https://www.swissadme.ch/index.php#>).

Figure 4: SwissTargetPrediction of Quercetin showing 90 potential protein targets.

Figure 5: Snapshot of protein-ligand interaction of quercetin and 3096 (AKT1)target

Figure 6: Grid box generation with centre X: 7.1909, Y: -3.4246 and Z: 11.3926, and Dimensions (Angstrom) X: 65.4634, Y: 80.3505 and Z: 73.6662. Making sure the macromolecule and ligand is inside the box.

Figure 7: visualization of protein target (pink) and 3O96/ AKT1 in blue showing interaction through PyMoL. Ligand is inside the cavity (binding site), not floating outside and properly oriented.

Figure 8: There are 10 Hydrogen bonds having distances of 2.9,2.9,3.0,3.0,3.1,3.1,3.2,3.23.3 and 3.3 Å. Showing strong bonding interaction with strong H-bond strength.

List of tables

Table 1: From PyRx showing binding affinities between quercetin and AKT1, lower the negative value stronger is the binding affinity. -9.7kcal/mol has the highest binding affinity showing strong interaction between the target protein and the ligand

Molecular Docking-Based Evaluation of Quercetin as a Multi-Target Therapeutic Agent in Estrogen-Associated Gallbladder Carcinogenesis.

Chapter 1 - Introduction

Gallbladder cancer (GBC) is a highly invasive malignancy of the biliary system, an organ

5 responsible for storing bile juice and aiding in the digestion and absorption of fats in the small intestine. Unfortunately, this disease is often diagnosed in its late stages and is associated with a notably poor prognosis (1,2). Among these risk factors, estrogen plays a pivotal and distinct role in gallbladder pathogenesis. Estrogen significantly alters cholesterol metabolism through the activation of HMG-CoA reductase, which increases the cholesterol supersaturation of bile. This process enhances mucin-mediated crystal nucleation and impairs gallbladder motility, ultimately resulting in gallstone formation and biliary stasis. Beyond stone formation, estrogen receptor-mediated signalling activates both the PI3K/AKT and MAPK pathways. This activation initiates cellular proliferation, anti-apoptosis, and angiogenesis, facilitating the epithelial transformation and multistep carcinogenesis that ultimately contribute to the development of gallbladder cancer (9,11).

11 Quercetin, a naturally occurring bioactive flavonoid, presents a promising solution. It is widely recognized for its significant anti-inflammatory, antioxidant, and anti-cancer properties, notably demonstrating the ability to target multiple biological pathways at once (12,13,19). However, its specific multi-target therapeutic efficacy and underlying mechanisms in the context of estrogen-driven gallbladder pathogenesis remain poorly understood.

36
2 Gallbladder cancer (GBC) is an aggressive malignancy arising from the epithelial lining of the gallbladder and represents the most common cancer of the biliary tract, although it remains relatively rare globally. The incidence of GBC shows marked geographic variation, with high prevalence reported in regions such as northern India, Chile, and parts of East Asia, suggesting a strong association with environmental, dietary, and genetic factors. Increasing age is another significant risk factor, with most cases occurring after the age of 50. Chronic inflammation of the gallbladder, particularly due to gallstones (cholelithiasis), is the most important predisposing factor, leading to continuous epithelial irritation and dysplasia. Additional risk factors include obesity, infections (e.g., *Salmonella typhi* carriers),

Objectives of the Study

Primary Objective

1. To evaluate the multi-target therapeutic potential of quercetin in estrogen-associated gallbladder carcinogenesis using molecular docking approach.

Secondary Objectives

2. To investigate the binding interactions and affinity of quercetin with key target proteins using molecular docking, thereby validating its potential role in modulating critical signaling pathways.

31 Chapter 2- Literature review

2.1

Overview of gallbladder carcinoma

Gallbladder carcinoma (GBC) is a malignant tumor arising from the epithelial lining of the gallbladder. It is the most common cancer of the biliary tract and is known for its aggressive nature and poor prognosis, mainly because it is often diagnosed at an advanced stage. Gallbladder carcinoma is a cancer that originates in the mucosal cells of the gallbladder, most commonly as adenocarcinoma ($\approx 90\text{--}95\%$) (1,2).

Adenocarcinoma forms gland-like structure and secrete mucus or from secretory structures from the glandular epithelial cells, it is developed in many organs that have glandular tissues and gall bladder is one of the organs. It is a malignant tumor and there is dysregulation with the major three pathways PI3K/Akt, MAPK and NF- κ B which results in faster growth of tumor and uncontrolled cell proliferation. Targeting this pathway with quercetin can help restore control (18). It has a higher incidence in regions such as Northern India, Chile, and Japan, and is strongly associated with gallstones (cholelithiasis), which represent the most important risk factor. Other contributing factors include chronic inflammation such as chronic cholecystitis, porcelain gallbladder (calcification of the gallbladder wall), gallbladder polyps larger than 1 cm, infections like *Salmonella typhi*, and lifestyle factors such as obesity and a high-fat diet (6,7).

The development of gallbladder cancer usually happens in a gradual, step-by-step manner starting with long-term irritation of the gallbladder lining, most commonly due to gallstones. These stones repeatedly injure the inner lining, causing chronic inflammation, which forces the normal cells to adapt for survival. As a result, the normal gallbladder epithelial cells change into a different type of cells (called metaplasia), which are better able to tolerate stress but are more unstable. Over time, these altered cells begin to show abnormal features such as irregular shape, enlarged nuclei, and loss of normal organization—this stage is called dysplasia and is considered precancerous. With continued damage and accumulation of genetic mutations, these dysplastic cells lose control over their growth and start invading surrounding tissues, leading to carcinoma (cancer) (3).

Microscopically, most gallbladder cancers are adenocarcinomas, meaning they arise from gland-forming cells, while less commonly they can be squamous cell carcinomas or adenosquamous carcinomas, which tend to be more aggressive (3).

Clinically, early stages are often asymptomatic, but as the disease progresses, patients may present with right upper abdominal pain, nausea, vomiting, jaundice (a late sign), weight loss, and sometimes a palpable mass in advanced stages. Diagnosis is primarily based on imaging techniques such as ultrasound, followed by CT scan or MRI, with tumor

markers like CA 19-9 and CEA providing supportive but non-specific information; definitive diagnosis is confirmed by biopsy. The prognosis is generally poor due to late detection, with a low 5-year survival rate, although outcomes improve significantly if the cancer is identified early and surgically removed (1,2,3).

2.2 Relation with Gallbladder Carcinoma and Estrogen

29 Estrogen increases the risk of gallbladder carcinoma indirectly, mainly by promoting gallstone formation and chronic inflammation. Estrogen plays a particularly significant role in driving the molecular mechanisms of gallbladder cancer. Estrogen alters cholesterol metabolism by activating the enzyme HMG-CoA reductase, which leads to the cholesterol supersaturation of bile. This promotes mucin-mediated crystal nucleation and impairs normal gallbladder motility, ultimately resulting in gallstone formation and biliary stasis (9).

Beyond the physical formation of stones, estrogen receptor-mediated signaling actively drives cancer progression by stimulating the PI3K/AKT and MAPK pathways. This activation promotes abnormal cell proliferation, prevents natural cell death (anti-apoptosis), all of which facilitate epithelial transformation and multistep carcinogenesis (10).

Gallbladder cancer occurrence is higher in women, these gallstones lead to chronic inflammation of the gallbladder (chronic cholecystitis), which can progress to carcinoma, and the disease is often detected relatively earlier. In contrast, men have a lower incidence because they lack this estrogen-related mechanism; their cases are more often linked to non-hormonal factors such as chronic inflammation or infections, and they typically present later with more aggressive disease and a poorer prognosis (6,7).

2.3 Quercetin as an Anticancer Compound

Quercetin is a natural plant-derived flavonoid with significant anticancer potential, primarily due to its ability to act through multiple biological mechanisms. It promotes apoptosis (programmed cell death) in cancer cells by regulating proteins like Bax and Bcl-2, inhibits uncontrolled cell division by inducing cell cycle arrest, and reduces oxidative damage through its antioxidant action against Reactive Oxygen Species. Additionally, it suppresses inflammation by inhibiting pathways such as NF- κ B, and prevents tumor growth by blocking angiogenesis and metastasis (12,13).

Although most evidence comes from laboratory and animal studies, quercetin is widely regarded as a promising chemopreventive agent, supporting cancer prevention rather than serving as a standalone therapeutic drug (13).

Research over the years has increasingly focused on Quercetin as a promising natural anticancer agent. In various studies, scientists observed that quercetin can push cancer cells toward apoptosis, essentially triggering a self-destruct mechanism that prevents their

uncontrolled growth. As the investigations deepened, it became clear that this compound does more than just kill cancer cells—it also slows down and suppresses overall tumor development. A key part of this effect lies in how quercetin interferes with major cellular signaling systems and the inflammatory regulator NF- κ B. By dampening these pathways, which normally help cancer cells survive, multiply, and spread, quercetin effectively disrupts the internal machinery that tumors rely on (15,19).

2.4 Quercetin and PI3K-AKT-mTOR Signaling

The Role of PI3K/AKT in Gallbladder Cancer: In estrogen-driven gallbladder pathogenesis, estrogen receptor-mediated signaling activates the PI3K/AKT pathway. This activation drives abnormal cell proliferation, prevents natural cell death (anti-apoptosis), and encourages angiogenesis, facilitating carcinogenesis (19). **Quercetin's Therapeutic Modulation:** Quercetin demonstrates significant therapeutic potential by modulating the PI3K/AKT pathway. By actively targeting this signaling cascade, quercetin helps reduce cellular proliferation and induces apoptosis (13,16).

Identification of Key Targets: Network pharmacology analysis reveals that genes associated with PI3K/AKT signaling, specifically AKT1 and PIK3CA, are major hub genes overlapping between quercetin targets and gallbladder disease mechanisms (17).

2.5 Estrogen Receptor and PI3K/AKT Crosstalk

“Estrogen receptor and PI3K/AKT crosstalk” means that the estrogen receptor and PI3K/AKT pathway interact and influence each other. When estrogen binds to its receptor, it activates signals that promote cell growth and also activates PI3K/AKT. At the same time, PI3K/AKT can activate estrogen receptors even without estrogen, forming a continuous loop that enhances tumor growth and survival (30,31,32,33).

2.6 Quercetin in Hormone-Related Disorders and Cancer

Acting as a phytoestrogen, it can bind to estrogen receptors and influence proliferation and apoptosis (34). It also inhibits PI3K activity and reduces AKT phosphorylation, thereby preventing abnormal activation of estrogen signaling. Additionally, quercetin regulates downstream targets like mTOR and apoptotic proteins, promoting apoptosis and inhibiting tumor growth (34).

2.7 Flavonoids Targeting PI3K/Akt/mTOR

Flavonoids such as quercetin, kaempferol, luteolin, and apigenin act as modulators of the PI3K/Akt/mTOR pathway. These compounds inhibit kinase activity, reduce phosphorylation events, and regulate downstream targets, resulting in reduced tumor growth and increased apoptosis (35).

They also exhibit antioxidant and anti-inflammatory effects by reducing ROS and inhibiting NF- κ B signaling, further contributing to anticancer activity (35).

2.8 Docking Methodology

Computational approaches for docking molecular compounds are used to predict ligand–protein interactions. It involves conformational sampling and scoring functions to estimate binding affinity (37).

35 The workflow includes protein preparation, ligand preparation, active site identification, docking simulation, and interaction analysis. Tools such as PyRx and AutoDock Vina are commonly used for docking studies (44).

Chapter 3 - Methodology

3.1 Computational resources and database used

This thesis aims to explore a methodological approach using molecular docking analysis for evaluating the therapeutic potential of quercetin in gallbladder disease.

3.1.1 Database and tool Utilized:

Chemical and Ligand Databases:

1 A). PubChem: (<https://pubchem.ncbi.nlm.nih.gov/>) used for Retrieval of 3D structure of quercetin and acquisition of SDF format and SMILES notation. Application is widely used as the primary source for ligand preparation (47).




Fig.1: 3D image (ball and stick) of quercetin obtained from pubchem. Co-ordinates are also downloaded in sdf format.

B). Structural Databases

25 Protein Data Bank (PDB):(<https://www.rcsb.org/>) Retrieval of 3D structures of target proteins (e.g., AKT1, PIK3CA, INSR). Here AKT1 is chosen as the protein target with the PDB ID-3O96.




Fig.2: 3D structure of AKT1(PDB ID-3O96) retrieved from protein data bank.

C). Target Prediction Tools : SwissTargetPrediction : (<http://www.swisstargetprediction.ch/>)
Prediction of potential protein targets of quercetin.

Fig. 3: SwissTargetPrediction

C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O (smile notation) from the pubchem to the SwissTargetPrediction website (<https://www.swissadme.ch/index.php#>).

Parameters used are -Organism: *Homo sapiens*, and
Output: List of probable targets based on chemical similarity.

PyRx: Virtual screening and molecular docking. It is a user-friendly interface. This tool is used in this thesis for docking purposes as it is simpler, faster and more user friendly (37,44).

AutoDock Vina (alternatively used for this study): Docking simulations give an output as binding affinity values in kcal/mol and binding energy. Their role is to predict ligand–protein interactions to show its affinity and energy (44).

E). Visualization Tools

PyMOL: Visualization of docking results and structural analysis of protein–ligand complexes (37).

Discovery Studio: Detailed interaction analysis and Identification of Hydrogen bonds and Hydrophobic interactions (20,37).

3.1.2 Software Utilized

PyMOL:

PyMOL is a widely used molecular visualization tool in computational biology and structural bioinformatics. It enables detailed visualization of protein–ligand complexes, allowing researchers to analyze structural conformations and binding interactions. In this study, PyMOL was used to visualize docking results and examine the spatial orientation of quercetin within the active sites of target proteins (37).

PyRx (with AutoDock Vina):

PyRx is an integrated virtual screening software that provides a user-friendly graphical interface for molecular docking studies. It incorporates AutoDock Vina as its docking engine, which utilizes a scoring function and efficient optimization algorithms to predict ligand–protein binding affinities. In this study, PyRx was employed for ligand preparation, energy minimization, and docking simulations, while AutoDock Vina calculated binding energies and generated multiple binding conformations (37,44).

Discovery Studio:

Discovery Studio is a comprehensive molecular modeling and visualization software used for analyzing protein–ligand interactions. It provides detailed insights into binding

mechanisms, including hydrogen bonding, hydrophobic interactions, and other non-covalent interactions. In this study, it was used to validate docking results and analyze interaction profiles of quercetin with target proteins (20,37).

3.2 Objective

3.2.1 Objective 1: Evaluation of Multi-Target Therapeutic Potential of Quercetin

Data Extraction

2 The 3-dimensional (3D) structure of the bioactive compound quercetin was retrieved from the PubChem database in SDF format. The canonical SMILES notation of quercetin was also obtained for further analysis. To identify potential protein targets of quercetin, the SMILES notation was submitted to the SwissTargetPrediction web server with Homo sapiens selected as the target organism. Additionally, disease-associated genes related to gallbladder carcinoma and estrogen signaling were collected from the GeneCards database using relevant keywords. The retrieved genes were filtered based on their relevance score to ensure strong association with disease pathogenesis (47,48,36).

Identification of Common Targets

21 To identify potential therapeutic targets, the predicted targets of quercetin were intersected with gallbladder disease-associated genes. This intersection analysis was performed using TBtools-II software, which generated a Venn diagram to identify overlapping genes. These common targets were considered as candidate targets through which quercetin may exert its therapeutic effects (36).

Ligand Preparation

9 The ligand molecule (quercetin) obtained from PubChem was prepared using PyRx software. Energy minimization was performed to achieve a stable conformation. The ligand file was then converted into the required docking format, ensuring proper torsion and charge assignment (44).

Molecular Docking Studies

28 Molecular docking was carried out using PyRx integrated with AutoDock Vina. The prepared protein was set as the receptor, and quercetin was treated as a flexible ligand. A defined grid box is created around the active site of the protein ensuring accurate docking(37,44).

Analysis and Visualization

22 The docking results were analyzed based on binding affinity values and interaction profiles. The best docking poses were selected and visualized using PyMOL and Discovery Studio software(20,37). Here interactions such as hydrogen bonding strength and bond number can be viewed for further confirmation other than binding affinity.

3.2.2 Objective 2: Molecular Docking-Based Validation of Target Proteins

Selection of Target Proteins

Key hub proteins identified from the network analysis were chosen for docking studies. The selection was based on their central role in pathways such as PI3K/AKT and estrogen signaling and taken from swisstargetPrediction, where potential targets are predicted (18).

Protein Structure Retrieval and Preparation

The 3D structures of selected proteins were retrieved from the Protein Data Bank (PDB). The structures were prepared by removing water molecules and co-crystallized ligands, followed by the addition of hydrogen atoms and optimization of the protein structure to ensure stability for docking (50).

Ligand Preparation

The quercetin ligand was prepared using PyRx software. Energy minimization was carried out to obtain a stable conformation, and the ligand file was converted into the required docking format with appropriate charge assignments (44).

Docking Simulation

Molecular docking simulations were performed using PyRx integrated with AutoDock Vina. The prepared protein structures were set as receptors, and quercetin was treated as a flexible ligand. Multiple docking poses were generated along with binding affinity scores (37,44).

Analysis of Docking Results

Docking results were evaluated based on binding affinity values (kcal/mol), where lower values indicated stronger binding interactions. The best docking conformations were selected for further analysis (37).

Visualization of Protein–Ligand Interactions

The selected docking poses were visualized using PyMOL and Discovery Studio. These tools were used to analyze hydrogen bonding, hydrophobic interactions, and other non-covalent interactions between quercetin and target proteins. This analysis helped validate the binding stability and therapeutic potential of quercetin (20,37).

Chapter 4- Results

4.1 Results as well as Discussion for Objective 1

Evaluation of the Multi-Target Therapeutic Potential of Quercetin


4.1.1 Results


Identification of Potential Targets

The target prediction analysis of quercetin using SwissTargetPrediction resulted in a total of 96 potential protein targets. Concurrently, 102 gallbladder disease-associated genes were retrieved from the GeneCards database based on relevance scores. Intersection analysis between these datasets identified 7 overlapping genes, which were considered as potential therapeutic targets involved in estrogen-associated gallbladder carcinogenesis.

www.swisstargetprediction.ch/result.php?job=1947297759&organism=Homo_sapiens

Query Molecule





Target Classes

Top 15
Top 25
Top 50
All

Export results:

Target	Common name	Uniprot ID	ChEMBL ID	Target Class	Probability*	Known actives (3D/2D)
Broad substrate specificity ATP-binding cassette transporter ABCG2	ABCG2	Q9UNQ0	CHEMBL5393	Primary active transporter		6 / 161
ALK tyrosine kinase receptor	ALK	Q9UM73	CHEMBL4247	Kinase		7 / 4
Carbonic anhydrase 14	CA14	Q9ULX7	CHEMBL3510	Lyase		52 / 13
Short transient receptor potential channel 5	TRPC5	Q9UL62	CHEMBL1250411	Voltage-gated ion channel		5 / 4
Inositol hexakisphosphate kinase 2	IP6K2	Q9UHH9	CHEMBL4523488	Transferase		9 / 10
Histone deacetylase 6	HDAC6	Q9UBN7	CHEMBL1865	Eraser		26 / 27
Sphingosine kinase 1	SPHK1	Q9NYA1	CHEMBL4394	Enzyme		2 / 2
NADPH oxidase 4	NOX4	Q9NPH5	CHEMBL1250375	Oxidoreductase		20 / 8
Serine/threonine-protein kinase Nek6	NEK6	Q9HC98	CHEMBL4309	Kinase		3 / 2
Aurora kinase B	AURKB	Q96GD4	CHEMBL2185	Kinase		10 / 5
Inositol polyphosphate multikinase	IPMK	Q8NFU5	CHEMBL4523401	Transferase		6 / 6
NAD-dependent protein deacetylase sirtuin-6	SIRT6	Q8N6T7	CHEMBL2163182	Eraser		4 / 2

Fig.4: SwissTargetPrediction of Quercetin showing 90 potential protein targets.

In the export results section, there are 100 potential protein targets and the “Probability” column indicates how likely the molecule is to interact with that protein. A value close to **1.0** means a very strong prediction based on similarity to known bioactive compounds. For the whole information of the exported result, the top hit along with the known active 3D/2D can be seen in the URL link https://www.swisstargetprediction.ch/result.php?job=1947297759&organism=Homo_sapiens


From these target predictions the biologically important cancer-related targets also known as hub genes are selected, they are AKT1, PIK3CA, EGFR, BRAF and SRC. For gallbladder cancer / PI3K-AKT pathway work, the AKT1 target is prioritized.

4.2 Results and Discussion for Secondary Objectives.

4.2.1 Molecular Docking Analysis (Objective 2)

Molecular docking studies were performed to validate the interaction between quercetin and selected hub proteins. Docking simulations using PyRx integrated with AutoDock Vina generated multiple binding conformations.

Among the selected targets, AKT1 showed the strongest binding affinity with quercetin, with a docking score of approximately -9.7 kcal/mol. Other proteins such as EGFR,



PIK3CA,
and INSR
also

demonstrated favorable binding affinities.

Fig.5: Snapshot of protein-ligand interaction of quercetin and 3096 (AKT1)target .

The interaction analysis revealed: Formation of hydrogen bonds with key amino acid residues, strong hydrophobic interactions within the binding pocket and Stable ligand orientation within the active site.

Ligand	Binding Affinity	rmsd/ub	rmsd/lb
3096_3096ligand_uff_E=379.98	-9.7	0	0
3096_3096ligand_uff_E=379.98	-9.6	3.415	1.775
3096_3096ligand_uff_E=379.98	-9.6	5.133	2.74
3096_3096ligand_uff_E=379.98	-9.4	3.936	2.122
3096_3096ligand_uff_E=379.98	-8.9	6.768	2.367
3096_3096ligand_uff_E=379.98	-8.8	9.014	5.226
3096_3096ligand_uff_E=379.98	-8.7	5.809	3.675
3096_3096ligand_uff_E=379.98	-8.5	12.545	7.838
3096_3096ligand_uff_E=379.98	-7.9	12.882	9.605

Table 1: From PyRx showing binding affinities between quercetin and AKT1, lower the negative value stronger is the binding affinity. -9.7kcal/mol has the highest binding affinity showing strong interaction between the target protein and the ligand.




Fig.6: Grid box generation with center X: 7.1909, Y: -3.4246 and Z: 11.3926, and Dimensions (Angstrom) X: 65.4634, Y: 80.3505 and Z: 73.6662. Making sure the macromolecule and ligand is inside the box.



Fig.7 : visualization of protein target (pink) and 3O96/ AKT1 in blue showing interaction through PyMOL. Ligand is inside the cavity (binding site), not floating outside and properly oriented.




Fig.8: There are 10 Hydrogen bonds having distances of 2.9,2.9,3.0,3.0,3.1,3.1,3.2,3.2,3.3 and 3.3 Å. Showing strong bonding interaction with strong H-bong strength.

These results indicate a strong and stable interaction between quercetin and the selected target proteins.

4.2.2. Validation of Therapeutic Potential through Docking

The molecular docking results provide strong evidence supporting the therapeutic potential of quercetin. The high binding affinity observed with key target proteins, particularly AKT1, indicates that quercetin can effectively interact with and potentially inhibit these proteins (19,20). The presence of stable hydrogen bonding and hydrophobic interactions further confirms the structural compatibility of quercetin with the active sites of these proteins. Such interactions are critical for effective inhibition of protein function and subsequent modulation of signalling pathways (20,37). By targeting proteins involved in PI3K/AKT and estrogen signalling pathways, quercetin may regulate key processes such as inflammation. This multi-target interaction profile enhances its potential as a therapeutic agent compared to conventional drugs that typically act on a single target (13,19,34).

CHAPTER – 5

CONCLUSION, FUTURE PERSPECTIVES AND SOCIAL IMPACT

5.1 Conclusion

Evaluating the multi-target therapeutic potential of quercetin in estrogen-associated gallbladder carcinogenesis. The findings highlight the complex molecular mechanisms underlying gallbladder cancer and emphasize the importance of targeting multiple pathways for effective treatment (19,20,36). Through the SwissTargetPrediction tool which acts as the network pharmacology tool, a total of seven overlapping gene targets were identified between quercetin and gallbladder disease-associated genes. Among these, key hub genes such as EGFR, AKT1, SRC, ESR2, and CYP19A1 were found to play crucial roles in disease progression. These genes are involved in critical biological processes including cell proliferation, apoptosis, inflammation, and hormone-mediated signalling (36,48). Functional enrichment analysis further revealed that these targets are significantly associated with major signalling pathways such as the PI3K/AKT pathway, estrogen signalling pathway, and cancer-related pathways, which are known to contribute to tumour growth and progression (18,19). The presence of stable hydrogen bonding and hydrophobic interactions confirmed the structural compatibility and potential inhibitory action of quercetin on these targets (20,37). Overall, the results indicate that quercetin exhibits significant potential as a multi-target therapeutic agent, capable of modulating key molecular pathways involved in estrogen-driven gallbladder carcinogenesis. This study provides a strong computational foundation for further experimental validation and drug development (13,19).

5.2 Future Perspectives

Although the present study provides valuable insights, it is primarily based on dry lab analysis, and further research is required to validate and expand these findings. Future studies should focus on validating the findings of this research through multiple experiments such as wet labs and clinical approaches. Initially, in vitro studies using appropriate cell lines are necessary to confirm the biological activity and anti-cancer effects of quercetin. Furthermore, clinical investigations are essential to assess the effectiveness and applicability of quercetin in human subjects suffering from gallbladder carcinoma (13,21). In addition to validation, emphasis should also be placed on the development of advanced drug delivery systems. Exploring combination therapy approaches, where quercetin is used alongside existing chemotherapeutic agents, may improve treatment outcomes and help reduce drug resistance (29). Lastly, further computational and experimental studies should be conducted to identify additional molecular targets and signaling pathways influenced by quercetin, thereby expanding its therapeutic potential (36).

5.3 Social Impact

Particularly in regions with high prevalence such as northern India (40,41) GBC cases are high. The findings of this study have important social and healthcare implications. Quercetin demonstrates significant potential as an affordable therapeutic agent due to its natural occurrence in commonly consumed fruits and vegetables, making it a cost-effective and accessible alternative to expensive conventional cancer treatments (43). The use of multi-target therapeutic agents such as quercetin may also improve treatment efficacy and reduce recurrence rates, ultimately lowering the overall disease burden associated with gallbladder cancer (13,19). In addition, this study underscores the growing importance of plant-derived compounds in modern drug discovery, thereby promoting further research in the field of nutraceuticals and natural products for therapeutic applications (43).

REFERENCES

1. Kumar V, Abbas AK, Aster JC. *Robbins and Cotran Pathologic Basis of Disease*. 10th ed. Elsevier; 2020.
2. Townsend CM, Beauchamp RD, Evers BM, Mattox KL. *Sabiston Textbook of Surgery: The Biological Basis of Modern Surgical Practice*. 21st ed. Elsevier; 2021.
3. O'Connell PR, Williams NS, McCaskie AW. *Bailey & Love's Short Practice of Surgery*. 28th ed. CRC Press; 2022.
4. World Health Organization. *WHO Classification of Tumours: Digestive System*

- Tumours*. 5th ed. IARC; 2019.
5. National Cancer Institute. *Gallbladder Cancer—Patient Version*.
 6. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. *Gut Liver*. 2012;6(2):172–187.
 7. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. *Clin Epidemiol*. 2014;6:99–109.
 8. Lazcano-Ponce EC, et al. Epidemiology and molecular pathology of gallbladder cancer. *CA Cancer J Clin*. 2001;51(6):349–364.
 9. Randi G, et al. Gallbladder cancer worldwide: geographical distribution and risk factors. *Int J Cancer*. 2006;118(7):1591–1602.
 10. Shukla VK, et al. Molecular biology of gallbladder cancer: potential targets for therapy. *J Surg Oncol*. 2008;97(6):543–548.
 11. Wang HH, et al. Estrogen receptors and cholesterol gallstone formation. *Hepatology*. 2017;65(6):2051–2063.
 12. D'Andrea G. Quercetin: A flavonol with multifaceted therapeutic applications? *Fitoterapia*. 2015;106:256–271.
 13. Tang SM, Deng XT, Zhou J, et al. Pharmacological basis and new insights of quercetin action in cancer treatment. *Biomed Pharmacother*. 2020;121:109604.
 14. Murakami A, Ashida H, Terao J. Multitargeted cancer prevention by quercetin. *Cancer Lett*. 2008;269(2):315–325.
 15. Russo M, et al. (2012). Quercetin and cancer (general mechanistic review).
 16. Reyes-Farias M, Carrasco-Pozo C. The anti-cancer effect of quercetin. *Nutrients*. 2019.
 17. Li Y, et al. Network pharmacology analysis of quercetin. 2021.
 18. Zhou Y, et al. Mechanisms of PI3K/AKT signaling in cancer. 2020.
 19. Zhang Q, Wen F, Sun F, et al. Quercetin inhibits PI3K-AKT signaling. 2022.
 20. Chen J, et al. Molecular docking validation studies. 2021.
 21. Hasan AMW, et al. Quercetin anticancer activity via PI3K-AKT-mTOR pathway. 2025.
 22. Eity TA, et al. Therapeutic efficacy of quercetin in cancer therapy. 2024.
 23. Guo Z, et al. Mechanism of action of quercetin in cellular signaling. *Front Med*. 2024.
 24. Biswas P, et al. Quercetin anticancer activities. *Int J Mol Sci*. 2022;23(19):11746.
 25. Sangeetha D, et al. Therapeutic potentials of quercetin. *Phytomedicine*. 2024.
 26. Carnazza M, et al. Natural compounds targeting PI3K/Akt signaling. 2025.
 27. Silva-Pinto PA, et al. Mechanisms and therapeutic potential of quercetin. *Heliyon*. 2025.
 28. Yang Y, et al. Quercetin regulates PI3K/Akt/mTOR pathway. *Viruses*. 2025;17(12):1637.
 29. Raghav A, et al. Nanoquercetin therapeutic potential. *Cells*. 2024;13(7):638.
 30. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. *Annu Rev Med*. 2011;62:233–247.
 31. Miller TW, et al. PI3K/AKT/mTOR and endocrine resistance. *J Clin Oncol*. 2011;29(33):4452–4461.
 32. Campbell RA, et al. PI3K/AKT-mediated activation of ER. *J Biol Chem*. 2001;276(13):9817–9824.

33. Fresno Vara JA, et al. PI3K/Akt signalling pathway and cancer. *Cancer Treat Rev.* 2004;30(2):193–204.
34. Jian X, et al. Therapeutic effects of quercetin in gynecological disorders. *Biomed Pharmacother.* 2024.
35. Zughabi TA, et al. Targeting PI3K/Akt/mTOR pathway by flavonoids. *Int J Mol Sci.* 2021;22(22):12455.
36. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol.* 2008;4(11):682–690.
37. Morris GM, Lim-Wilby M. Molecular docking. *Methods Mol Biol.* 2008;443:365–382.
38. Bastin A, Teimouri M, Faramarz S, et al. In vitro and molecular docking analysis of quercetin. *Curr Pharm Des.* 2023.
39. Hanahan D, Weinberg RA. Hallmarks of cancer. *Cell.* 2011;144:646–674.
40. Bray F, et al. Global cancer statistics. *CA Cancer J Clin.* 2018;68:394–424.
41. Siegel RL, et al. Cancer statistics. *CA Cancer J Clin.* 2023;73:17–48.
42. Aggarwal BB, et al. Inflammation and cancer. *Biochem Pharmacol.* 2006;72:1605–1621.
43. Newman DJ, Cragg GM. Natural products in drug discovery. *J Nat Prod.* 2020;83:770–803.
44. Trott O, Olson AJ. AutoDock Vina: docking software. *J Comput Chem.* 2010;31:455–461.
45. Szklarczyk D, et al. STRING database. *Nucleic Acids Res.* 2021;49:D605–D612.
46. Shannon P, et al. Cytoscape: network analysis tool. *Genome Res.* 2003;13:2498–2504.
47. Kim S, et al. PubChem database update. *Nucleic Acids Res.* 2021;49:D1388–D1395.
48. Stelzer G, et al. GeneCards database. *Curr Protoc Bioinformatics.* 2016;54:1.30.1–1.30.33.
49. Kuleshov MV, et al. Enrichr: gene set enrichment tool. *Nucleic Acids Res.* 2016;44:W90–W97.
50. Berman HM, et al. Protein Data Bank. *Nucleic Acids Res.* 2000;28:235–242.
51. Wishart DS, et al. DrugBank database. *Nucleic Acids Res.* 2018;46:D1074–D1082.
52. Hopkins AL. Network pharmacology concepts in drug discovery. *Nat Biotechnol.* 2007;25:1110–1111.